These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 34579284)
1. Neutralizing Antibodies against SARS-CoV-2, Anti-Ad5 Antibodies, and Reactogenicity in Response to Ad5-nCoV (CanSino Biologics) Vaccine in Individuals with and without Prior SARS-CoV-2. Hernández-Bello J; Morales-Núñez JJ; Machado-Sulbarán AC; Díaz-Pérez SA; Torres-Hernández PC; Balcázar-Félix P; Gutiérrez-Brito JA; Lomelí-Nieto JA; Muñoz-Valle JF Vaccines (Basel); 2021 Sep; 9(9):. PubMed ID: 34579284 [TBL] [Abstract][Full Text] [Related]
2. Comparison of three different COVID-19 vaccine platforms (CoronaVac, BTN162b2, and Ad5-nCoV) in individuals with and without prior COVID-19: Reactogenicity and neutralizing antibodies. Morales-Núñez JJ; Muñoz-Valle JF; Machado-Sulbarán AC; Díaz-Pérez SA; Torres-Hernández PC; Panduro-Espinoza BV; Gallegos-Díaz de Leon JA; Munguía-Ramirez CD; Hernández-Bello J Immunol Lett; 2022 Dec; 251-252():20-28. PubMed ID: 36279685 [TBL] [Abstract][Full Text] [Related]
4. Neutralizing antibody responses to the Delta variant of SARS-CoV-2 following vaccination with Ad5-nCoV (CanSino) in the Mexican population. Hernández-Bello J; Lorenzo-Leal AC; Muñoz-Valle JF; Morales-Núñez JJ; Díaz-Pérez SA; Hernández-Gutiérrez R; Bach H PLoS One; 2024; 19(4):e0299520. PubMed ID: 38573914 [TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 vaccine-induced antibody and T cell response in SARS-CoV-1 survivors. Duan LJ; Cui XM; Zhu KL; Yao L; Wang GL; Cao WC; Ma MJ Cell Rep; 2022 Aug; 40(9):111284. PubMed ID: 35987196 [TBL] [Abstract][Full Text] [Related]
6. IgG Antibodies Generation and Side Effects Caused by Ad5-nCoV Vaccine (CanSino Biologics) and BNT162b2 Vaccine (Pfizer/BioNTech) among Mexican Population. Guzmán-Martínez O; Guardado K; de Guevara EL; Navarro S; Hernández C; Zenteno-Cuevas R; Montero H Vaccines (Basel); 2021 Sep; 9(9):. PubMed ID: 34579236 [TBL] [Abstract][Full Text] [Related]
7. Safety and Immunogenicity of Homologous Recombinant Adenovirus Type 5-Vectored COVID-19 Vaccine Booster Dose in Healthy Adults Aged 18-60 Years: a Single-Center, Open-Label Trial. Jia S; Zhang J; Wang X; Zhang Z; Wang B; Zhang J; Jiang H; Guo G; Wang Y; Wan J; Wang W; Hou L; Zhu F Infect Dis Ther; 2023 Dec; 12(12):2757-2769. PubMed ID: 38038866 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of the effectiveness and safety of sequential vaccination with inactivated SARS-CoV-2 vaccine and Ad5-nCoV booster in pediatric liver transplant recipients. Zheng Z; Wu H; Sun X; Lu Y; Song Y; Luo Y; Zhou T; Feng M; Wan P; Zhu J; Shen N; Cao Q; Liang J; Xia Q; Xue F J Med Virol; 2024 Mar; 96(3):e29543. PubMed ID: 38528839 [TBL] [Abstract][Full Text] [Related]
9. Effect of Heterologous Vaccination Regimen with Ad5-nCoV CanSinoBio and BNT162b2 Pfizer in SARS-CoV-2 IgG Antibodies Titers. Romero-Ibarguengoitia ME; Rivera-Salinas D; Hernández-Ruíz YG; Armendariz-Vázquez AG; González-Cantú A; Barco-Flores IA; González-Facio R; Montelongo-Cruz LP; Del Rio-Parra GF; Sanz-Sánchez MÁ Vaccines (Basel); 2022 Mar; 10(3):. PubMed ID: 35335024 [TBL] [Abstract][Full Text] [Related]
10. Study of efficacy and antibody duration to fourth-dose booster of Ad5-nCoV or inactivated SARS-CoV-2 vaccine in Chinese adults: a prospective cohort study. Xu N; Xu Y; Dai R; Zheng L; Qin P; Wan P; Yang Y; Jiang J; Zhang H; Hu X; Lv H Front Immunol; 2023; 14():1244373. PubMed ID: 37736100 [TBL] [Abstract][Full Text] [Related]
11. Comparison of antibody persistency through one year between one-dose and two-dose regimens of Ad5-nCoV vaccine for COVID-19. Feng JL; Wang WJ; Jin PF; Zheng H; Jin LR; Xia X; Zhang XY; Li ZP; Li JX; Zhu FC Hum Vaccin Immunother; 2023 Aug; 19(2):2230760. PubMed ID: 37428653 [TBL] [Abstract][Full Text] [Related]
12. Boosting with an aerosolized Ad5-nCoV elicited robust immune responses in inactivated COVID-19 vaccines recipients. Zhang Z; Wu S; Liu Y; Li K; Fan P; Song X; Wang Y; Zhao Z; Zhang X; Shang J; Zhang J; Xu J; Li Y; Li Y; Zhang J; Fu K; Wang B; Hao M; Zhang G; Long P; Qiu Z; Zhu T; Liu S; Zhang Y; Shao F; Lv P; Yang Y; Zhao X; Sun Y; Hou L; Chen W Front Immunol; 2023; 14():1239179. PubMed ID: 37868993 [TBL] [Abstract][Full Text] [Related]
13. Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2. Havervall S; Marking U; Greilert-Norin N; Ng H; Gordon M; Salomonsson AC; Hellström C; Pin E; Blom K; Mangsbo S; Phillipson M; Klingström J; Hober S; Nilsson P; Åberg M; Thålin C EBioMedicine; 2021 Aug; 70():103523. PubMed ID: 34391088 [TBL] [Abstract][Full Text] [Related]
14. Neutralizing antibodies levels are increased in individuals with heterologous vaccination and hybrid immunity with Ad5-nCoV in the north of Mexico. Cervantes-Luevano K; Espino-Vazquez AN; Flores-Acosta G; Bernaldez-Sarabia J; Cabanillas-Bernal O; Gasperin-Bulbarela J; Gonzalez-Sanchez R; Comas-Garcia A; Licea-Navarro AF PLoS One; 2022; 17(6):e0269032. PubMed ID: 35749390 [TBL] [Abstract][Full Text] [Related]
15. A China-developed adenovirus vector-based COVID-19 vaccine: review of the development and application of Ad5-nCov. Wang SY; Liu WQ; Li YQ; Li JX; Zhu FC Expert Rev Vaccines; 2023; 22(1):704-713. PubMed ID: 37501516 [TBL] [Abstract][Full Text] [Related]
17. The investigation of the dynamics of changes in neutralizing antibody titers against type 5 adenovirus in the context of vaccination against a new coronavirus infection. Amosova IV; Timoshicheva TA; Kadyrova RA; Zabrodskaya YA; Vakin VS; Grudinin MP; Dzytseva VV; Khmelevsky MS; Lioznov DA Virology; 2024 Jun; 594():110051. PubMed ID: 38489915 [TBL] [Abstract][Full Text] [Related]
18. Vaccination with Adenovirus Type 5 Vector-Based COVID-19 Vaccine as the Primary Series in Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 1/2 Clinical Trial. Zhu Y; Tang R; Li X; Chen X; Wang X; Wang Y; Wang R; Zhu F; Li J Vaccines (Basel); 2024 Mar; 12(3):. PubMed ID: 38543926 [TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines. Rogliani P; Chetta A; Cazzola M; Calzetta L Vaccines (Basel); 2021 Mar; 9(3):. PubMed ID: 33807818 [No Abstract] [Full Text] [Related]
20. SARS-CoV-2 Neutralizing Antibody Levels Post COVID-19 Vaccination Based on ELISA Method-A Small Real-World Sample Exploration. Li X; Liang C; Xiao X Vaccines (Basel); 2021 Oct; 9(10):. PubMed ID: 34696247 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]